Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50911 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL14889462 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11645490 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL6507028 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL9360142 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL7673902 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11882526 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11771376 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL11882927 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG | |
| SCHEMBL8131815 | 1.00 | CNR2 (0.35) | CNR2DPP4EBPSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | claimed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| EP-0431955-B1 | 3-Amino-2-hydroxybornane derivatives, asymmetric Michael reaction using the same, and process for preparing optically active muscone utilizing Michael reaction | NIPPON MINING CO (JP) | 1994-03-30 | — | — | EP | claimed |
| EP-0431955-A2 | 3-Amino-2-hydroxybornane derivatives, asymmetric Michael reaction using the same, and process for preparing optically active muscone utilizing Michael reaction | NIKKO KYODO CO., LTD. (JP) | 1991-06-12 | — | — | EP | claimed |
| JP-3236357-A | — | — | None | — | — | JP | disclosed |
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2401280-A1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | Bristol-Myers Squibb Company (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099159-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-02 | — | — | WO | disclosed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| EP-0431955-A2 | 3-Amino-2-hydroxybornane derivatives, asymmetric Michael reaction using the same, and process for preparing optically active muscone utilizing Michael reaction | NIKKO KYODO CO., LTD. (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0431955-A2 | 3-Amino-2-hydroxybornane derivatives, asymmetric Michael reaction using the same, and process for preparing optically active muscone utilizing Michael reaction | NIKKO KYODO CO., LTD. (JP) | 1991-06-12 | — | — | EP | disclosed |
| EP-0431955-A2 | 3-Amino-2-hydroxybornane derivatives, asymmetric Michael reaction using the same, and process for preparing optically active muscone utilizing Michael reaction | NIKKO KYODO CO., LTD. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4130563-A | POLYMER INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-12-19 | — | — | US | disclosed |
| US-3988362-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3860724-A | SUBSTITUTED SULFONYL UREA AND ITS STEREOISOMERS AS HYPOGLYCEMIC AGENTS | HOFFMANN LA ROCHE | 1975-01-14 | — | — | US | disclosed |
| US-3832397-A | PROCESS FOR SUBSTITUTED SULFONYLUREAS | HOFFMANN LA ROCHE | 1974-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | CNR1, CNR2, GPR18 | CNR2 2/4885DPP4 3962/4885EBP 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.